US EditionBayer proposes US$10.25 billion plan for all Roundup cancer cases
The settlement aims to resolve most U.S. claims alleging Roundup caused Non-Hodgkins lymphoma with a capped 21-year payout program totaling about $10.25 billion.
- Bayer's Monsanto unit filed a proposed U.S. class settlement totaling US$7.25 billion to resolve current and future claims that Roundup caused Non-Hodgkins lymphoma on Tuesday.
- After buying Monsanto, Bayer has faced longstanding litigation and is preparing about 5 billion euros in additional settlements for existing U.S. Roundup cases.
- The proposed nationwide settlement would establish a long-term claims program funded by capped annual payments over up to 21 years and let eligible claimants diagnosed before Tuesday file claims.
- Bayer said it expects provisions and litigation liabilities to rise from 7.8 billion euros to 11.8 billion euros, anticipates around 5 billion euros in payouts in 2026, and postponed its 2025 results and 2026 guidance to March 4.
- If approved by a judge, the proposal filed before a judge in St. Louis, Missouri on Tuesday will cover the majority of cases pending in U.S. state and federal courts.
25 Articles
25 Articles
Bayer's subsidiary Monsanto has concluded a collective comparison in the United States to settle the claims for cancer risks from the plant protection product glyphosate. The company announced that $7.25 billion can be paid over a period of up to 21 years.
HOLLAND LAW FIRM ANNOUNCES MONSANTO AGREEMENT TO PAY UP TO $7.25 BILLION IN NATIONWIDE SETTLEMENT TO COMPENSATE THOSE DIAGNOSED WITH NON-HODGKIN LYMPHOMA FROM ROUNDUP WEEDKILLER EXPOSURE
/PRNewswire/ -- Eric D. Holland of the Holland Law Firm, serving as lead counsel for all future claimants, today announced the filing of a $7.25 billion...
Bayer proposes US$10.25 billion plan for all Roundup cancer cases
Bayer said on Tuesday that its Monsanto unit had filed a proposed U.S. class settlement totalling as much as US$7.25 billion that was aimed at resolving current and future claims that its Roundup weedkiller caused Non‑Hodgkins lymphoma.
The Group closes a collective comparison in the USA for the settlement of the glyphosate claims. Bayer pays a maximum of $7.25 billion over 21 years. The share withdraws.
Bayer subsidiary Monsanto agrees on $7.25 billion to settle glyphosate disputes.
Coverage Details
Bias Distribution
- 68% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
